Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
ADPT submitted a Form 144 notice reporting proposed sales of common stock.
The filing lists a proposed sale of 5,000 common shares tied to previously exercised stock options dated 01/25/2022. The excerpt also discloses recent 10b5-1 sales by Susan Bobulsky: 11,000 shares on 06/04/2026 for $198,000 and 5,000 shares on 06/11/2026 for $95,000.
Adaptive Biotechnologies Corporation issued $345 million of 0% Convertible Senior Notes due 2031 in a private offering to qualified institutional buyers. The notes are senior unsecured obligations, carry no cash interest, and are convertible into common stock at an initial price of about $24.11 per share, a 40% premium to the June 16, 2026 share price of $17.22.
The company expects net proceeds of about $334.5 million, of which it used $156.9 million to repay in full its revenue interest obligations under the OrbiMed Purchase Agreement, $25.6 million to fund capped call transactions, and $25.0 million to repurchase 1,451,800 shares of common stock in privately negotiated transactions. The remainder will support general corporate purposes and initiatives in its minimal residual disease (MRD) business. Capped call transactions with a cap price of $34.44 per share are designed to reduce potential dilution or excess cash payments upon conversion, subject to limitations.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of company common stock. He sold 100,000 shares on June 15, 2026 at a weighted-average price of $17.37 per share and 6,160 shares on June 16, 2026 at a weighted-average price of $18.01 per share.
All transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After these sales, Robins directly holds 1,405,898 shares of Adaptive Biotechnologies common stock.
Harlan Robins reported sales of common stock under Form 144, indicating dispositions of 100,000 and 10,000 shares. The filing notes the securities were acquired as Performance Awards on 03/07/2026. Transaction proceeds shown are $1,737,460 and $148,323.94.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 5,000 shares of common stock at $19.00 per share on June 11, 2026. After this transaction, she directly holds 411,775 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.
Harlan Robins submitted a Rule 144 notice to sell 10,000 shares of Common Stock on 04/08/2026.
The filing also lists recent compensatory issuances: 47,504, 41,246, and 11,250 shares were recorded as "Acquired as compensation -- Performance Awards" on 03/07/2026. A header line shows 160,044,392 shares with an associated date of 06/15/2026 as a contextual figure.
Adaptive Biotechnologies plans a private offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million, and intends to use proceeds for capped call transactions, up to $25 million of share repurchases and repayment of its OrbiMed revenue interest agreement.
The company is also pursuing a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, aiming to choose a preferred path by year-end 2026. MRD has grown revenue from $103 million in 2023 to $212 million in 2025 and reported $15 million of 2025 adjusted EBITDA, while Immune Medicine has built a large immune-receptor dataset and discovery platform.
ADPT filed a Form 144 notice listing a proposed sale of 5,000 shares of Common stock through Morgan Stanley Smith Barney LLC with a listed value of $85,350 and an associated date of 06/11/2026.
The filing also discloses recent 10b5-1 sales by Susan Bobulsky of 11,000 shares on 06/04/2026 for $198,000. The excerpt lists 160,044,392 shares outstanding as of 06/11/2026 as a context figure.